Great Debate: should we still target triglycerides to decrease cardiovascular risk?
Event: ESC Congress 2023
Topic: Lipids
Session type: Great Debates
Are we achieving guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals in real life?
Event: ESC Congress 2023
Topic: Lipid-Lowering Agents
Session type: Satellite Symposium
Combination therapy at the heart of lipid lowering management
Event: ESC Preventive Cardiology 2023
Topic: Lipid-Lowering Agents
Session type: Satellite Symposium
EAS Consensus on Lp(a) 2022 - what to measure, in whom to measure, how to interpret and what to do
Event: ESC Congress 2022
Topic: Lipids
Session type: Symposium
Dyslipidemia Challenge - Closing the Gap Between Guidelines and Clinical Practice
Event: ESC Congress 2021 - The Digital Experience
Topic: PCSK9-Antagonists
Session type: Satellite Symposium
Lipid lowering beyond LDL-cholesterol and statins
Event: ESC Congress 2021 - The Digital Experience
Topic: Pharmacology and Pharmacotherapy
Session type: Cardiology Toolbox
Managing patients with dyslipidaemia: how to tackle clinical inertia
Event: ESC Congress 2020
Topic: Drug therapy
Session type: Industry Q&A session
Lipid Treatment in very high risk ASCVD patient
Event: ESC Congress 2019
Topic: Lipids
Session type: Symposium
2019 ESC/EAS Guidelines on Dyslipidaemias
Event: ESC Congress 2019
Topic: Lipids
Session type: New ESC Guidelines
Meet the Task Force of the 2019 ESC/EAS Guidelines on Dyslipidaemias
Event: ESC Congress 2019
Topic: Lipids
Session type: Special Session
ESC 365 is supported by
